Bessemer Group
IOVA icon

Bessemer Group’s Iovance Biotherapeutics IOVA Stock Holding History

Bessemer Group’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-169
Closed – – 2600
2025
Q2 		$0 Hold
169
– – ﹤0.01% 2520
2025
Q1 		$1K Sell
169
-6
-3% -$31 ﹤0.01% 2348
2024
Q4 		$1K Hold
175
– – ﹤0.01% 2358
2024
Q3 		$2K Buy
+175
New +$1.66K ﹤0.01% 2215

Other funds holding IOVA

MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bessemer Group's IOVA Position: Q3 2025 in Review

Bessemer Group sold out of Iovance Biotherapeutics (IOVA) in Q3 2025, closing a stake of 169 shares.

Bessemer Group first reported a position in IOVA in Q3 2024 and held it in 4 quarters. The position peaked at $2K in Q3 2024. 253 funds tracked by Wall St. Rank hold IOVA as of Q3 2025.

  • Bessemer Group reported no remaining Iovance Biotherapeutics position as of Q3 2025 after selling out during the quarter.
  • Bessemer Group sold 169 Iovance Biotherapeutics shares in Q3 2025.
  • Bessemer Group first reported a position in Iovance Biotherapeutics in Q3 2024 and held it in 4 quarters.
  • Bessemer Group's Iovance Biotherapeutics position peaked at $2K in Q3 2024.
  • 253 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2025.

Based on Bessemer Group's 13F filing for Q3 2025, filed 5 Nov 2025.